- Home
- RUM vs NVAX Comparison
RUM vs NVAX Comparison
Compare RUM & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RUM
- NVAX
- Stock Information
- Founded
- RUM 2013
- NVAX 1987
- Country
- RUM United States
- NVAX United States
- Employees
- RUM N/A
- NVAX N/A
- Industry
- RUM Computer Software: Prepackaged Software
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RUM Technology
- NVAX Health Care
- Exchange
- RUM Nasdaq
- NVAX Nasdaq
- Market Cap
- RUM 2.9B
- NVAX 1.3B
- IPO Year
- RUM N/A
- NVAX 1995
- Fundamental
- Price
- RUM $9.23
- NVAX $6.60
- Analyst Decision
- RUM Buy
- NVAX Buy
- Analyst Count
- RUM 2
- NVAX 5
- Target Price
- RUM $15.00
- NVAX $16.60
- AVG Volume (30 Days)
- RUM 3.1M
- NVAX 5.5M
- Earning Date
- RUM 08-11-2025
- NVAX 08-07-2025
- Dividend Yield
- RUM N/A
- NVAX N/A
- EPS Growth
- RUM N/A
- NVAX N/A
- EPS
- RUM N/A
- NVAX 2.97
- Revenue
- RUM $101,461,524.00
- NVAX $1,254,962,000.00
- Revenue This Year
- RUM $19.22
- NVAX $56.85
- Revenue Next Year
- RUM $36.85
- NVAX N/A
- P/E Ratio
- RUM N/A
- NVAX $2.22
- Revenue Growth
- RUM 25.14
- NVAX 25.92
- 52 Week Low
- RUM $4.92
- NVAX $5.01
- 52 Week High
- RUM $17.40
- NVAX $17.81
- Technical
- Relative Strength Index (RSI)
- RUM 52.75
- NVAX 42.34
- Support Level
- RUM $8.13
- NVAX $6.26
- Resistance Level
- RUM $9.54
- NVAX $6.60
- Average True Range (ATR)
- RUM 0.47
- NVAX 0.27
- MACD
- RUM 0.02
- NVAX -0.06
- Stochastic Oscillator
- RUM 68.90
- NVAX 15.94
About RUM Rumble Inc.
Rumble Inc is a free-to-use video-sharing platform where users can watch, share, like, comment, and upload their own videos. Users can subscribe to channels to stay in touch with recent creator content and access video-on-demand uploaded, and live content streamed, by creators. Geographically, it generates a majority of its revenue from the United States.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.